
Beyond CRISPR: New Tools Enable Large-Scale Gene Replacement
New gene-editing technologies are emerging to overcome the limitations of CRISPR-Cas9, specifically its inability to efficiently insert large DNA segments. Techniques like PASTE, evoCAST, and recombineering allow researchers to replace entire faulty genes or engineer complex cellular circuits, addressing diseases with multiple genetic variants. While these methods offer broader therapeutic potential, they face significant challenges in delivery efficiency and complexity. The global CRISPR market is projected to grow at 16% annually, driven by these advancements and expanding clinical trials.













